<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865369</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-392</org_study_id>
    <nct_id>NCT02865369</nct_id>
  </id_info>
  <brief_title>Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment</brief_title>
  <acronym>RELIF-C</acronym>
  <official_title>Regression of Liver Fibrosis Assessed by Transient Elastography After Daclatasvir and Asunaprevir Combined Treatment in Advanced Fibrotic/Cirrhotic Patients With Chronic Hepatitis C Genotype 1b Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sang Gyune Kim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Boramae Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University Seoul Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ewha Womans University Mokdong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Soonchunhyang University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study on regression of liver fibrosis assessed by transient elastography after Daclatasvir
      and Asunaprevir combined treatment in advanced fibrotic/cirrhotic patients with chronic
      hepatitis C genotype 1b Infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The measurement of liver stiffness by transient elastography (TE) has been shown to correlate
      with the hepatic fibrosis stage and to have considerable accuracy for the diagnosis of
      cirrhosis in patients with chronic hepatitis C. Previous studied reported that liver
      stiffness is significantly reduced in SVR patients with pegylated interferon (IFN) and
      ribavirin treatment. Once a patient achieve sustained virological response (SVR), and
      resultingly lower liver stiffness score than baseline value, it is believed that he will have
      a better long-term outcome due to the improvement of liver fibrosis.

      Daclatasvir(DCV) and Asunaprevir(ASV) combined treatment showed a greater SVR rate in CHC
      compared to IFN based therapy. The investigators hypothesize that DCV and ASV combined
      treatment may achieve the improvement of liver stiffness measured by TE and a more favorable
      clinical outcomes in patients with advanced liver fibrosis. The investigators will also
      compare the change of fibrosis stage assessed by TE between this study subjects and those
      treated with other DAA agents during same observational period.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>The change of liver fibrosis stage at 48 weeks assessed by transient elastography in patients treated with Daclatasvir and Asunaprevir</measure>
    <time_frame>baseline to 48weeks</time_frame>
    <description>To compare the change of liver fibrosis stage (defined as F3, ≥8; F4, ≥12) assessed by transient elastography between baseline and 48 weeks in advanced fibrotic/cirrhotic Chronic Hepatitis C patients who achieved sustained virological response with Daclatasvir and Asunaprevir combined treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who were treated with Daclatasvir and Asunaprevir achieved SVR12 assessed by HCV RNA</measure>
    <time_frame>baseline to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who maintained sustained virologic response at SVR24, SVR72, SVR120, SVR168, and SVR216.</measure>
    <time_frame>baseline to 48weeks, 96weeks, 144weeks, 192weeks, 240weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of liver fibrosis stage assessed by transient elastography at 96weeks, 144weeks, 192weeks, 240weeks in patients treated with Daclatasvir and Asunaprevir</measure>
    <time_frame>baseline to 96weeks, 144weeks, 192weeks, 240weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of AST to Platelet Ratio Index</measure>
    <time_frame>baseline to 48weeks, 96weeks, 144weeks, 192weeks, 240weeks</time_frame>
    <description>APRI = [(AST/upper limit of normal)/platelet count]x100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Fibrosis 4 (Fib-4) index</measure>
    <time_frame>baseline to 48weeks, 96weeks, 144weeks, 192weeks, 240weeks</time_frame>
    <description>FIB-4 = age (years) × AST [IU/L] / [platelet count × sqr(ALT [IU/L])]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of change of liver fibrosis stage assessed by transient elastography between Daclatasvir and Asunaprevir combined treatment versus other DAA treatment</measure>
    <time_frame>baseline to 48weeks, 96weeks, 144weeks, 192weeks, 240weeks</time_frame>
    <description>Comparison of change of liver fibrosis stage assessed by transient elastography at 48weeks, 96weeks, 144weeks, 192weeks, 240weeks between Daclatasvir and Asunaprevir combined treatment versus other DAA treatment during same observational period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the incidence of hepatocellular carcinoma or liver cirrhosis complications between Daclatasvir and Asunaprevir combined treatment versus other DAA treatment</measure>
    <time_frame>baseline to 48weeks, 96weeks, 144weeks, 192weeks, 240weeks</time_frame>
    <description>Compare the incidence of hepatocellular carcinoma or liver cirrhosis complications at 48weeks, 96weeks, 144weeks, 192weeks, 240weeks between Daclatasvir and Asunaprevir combined treatment versus other Direct antiviral agents during same observational period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Fibrometer score</measure>
    <time_frame>baseline to 48weeks, 96weeks, 144weeks, 192weeks, 240weeks</time_frame>
    <description>alpha2 macroglobulin, GGT, AST, ALT, prothrombin index, urea, platelet count</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">103</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Daclatasvir plus Asunaprevir treatment</arm_group_label>
    <description>Among patients taking Daclatasvir and Asunaprevir combined treatment and having advanced liver fibrosis assessed by transient elastography</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir and Asunaprevir</intervention_name>
    <description>Daclatasvir and Asunaprevir combined treatment will not be assigned to the enrolled patients, but the patients who are treated with Daclatasvir and Asunaprevir will be included in this observational study.</description>
    <arm_group_label>Daclatasvir plus Asunaprevir treatment</arm_group_label>
    <other_name>Daclatasvir and Asunaprevir combined treatment for 24 weeks</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      8cc serum sample for the evaluation of direct liver fibrosis marker
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Genotype 1b, advanced fibrotic/cirrhotic Korean patients with chronic hepatitis C aged over
        18, without baseline NS5A RAVs (Y93 and/or L31)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronically infected with Hepatitis C virus genotype 1b

          -  HCV RNA ≥ 10^4 IU/mL (10,000 IU/mL)

          -  Chronic Hepatitis C with advanced fibrosis or cirrhosis (defined as ≥F3, ≥8
             kilopascals)

          -  Treatment-naïve or those who previously failed to treatment with peg-interferon alfa
             and ribavirin

          -  Women of childbearing potential (WOCBP) and men, who use effective methods of birth
             control

        Exclusion Criteria:

          -  Patients with baseline key NS5A RAVs (Y93 and/or L31)

          -  Estimated GFR &lt; 30mL/min without hemodialysis

          -  Alanine aminotransferase (ALT) &gt; 100 IU/L

          -  Coinfection with other hepatitis virus or human immunodeficiency virus

          -  A daily alcohol intake &gt;30 g

          -  Decompensated liver disease or hepatocellular carcinoma, liver or any other organ
             transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Gyune Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang Gyune Kim, Professor</last_name>
    <phone>82-32-621-5071</phone>
    <email>mcnulty@schmc.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Soonchunhyang University Cheonan Hospital</name>
      <address>
        <city>Cheonan</city>
        <state>Chungcheongnam-do</state>
        <zip>31151</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SaeHwan Lee, Professor</last_name>
    </contact>
    <investigator>
      <last_name>SaeHwan Lee, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi do</state>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Gyune Kim, Professor</last_name>
      <phone>82-32-621-5079</phone>
      <email>mcnulty@schmc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sang Gyune Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-do</state>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Kul Jung, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Young Kul Jung, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Jung-gu</city>
        <state>Incheon</state>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Woo Lee, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Jin-Woo Lee, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oh Sang Kwon, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Oh Sang Kwon, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Yong Park, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Jun Yong Park, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04401</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Young Jang, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Jae Young Jang, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanyang university hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dae Won Jun, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Dae Won Jun, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07985</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Hun Kim, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Tae Hun Kim, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wonju severance christian hospital</name>
      <address>
        <city>Wonju</city>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moon young Kim, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Moon young Kim, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005 Jan;41(1):48-54.</citation>
    <PMID>15690481</PMID>
  </reference>
  <reference>
    <citation>Hézode C, Castéra L, Roudot-Thoraval F, Bouvier-Alias M, Rosa I, Roulot D, Leroy V, Mallat A, Pawlotsky JM. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther. 2011 Sep;34(6):656-63. doi: 10.1111/j.1365-2036.2011.04765.x. Epub 2011 Jul 13.</citation>
    <PMID>21752038</PMID>
  </reference>
  <reference>
    <citation>Arima Y, Kawabe N, Hashimoto S, Harata M, Nitta Y, Murao M, Nakano T, Shimazaki H, Kobayashi K, Ichino N, Osakabe K, Nishikawa T, Okumura A, Ishikawa T, Yoshioka K. Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C. Hepatol Res. 2010 Apr;40(4):383-92. doi: 10.1111/j.1872-034X.2009.00618.x. Epub 2010 Mar 4.</citation>
    <PMID>20236358</PMID>
  </reference>
  <reference>
    <citation>Wang JH, Changchien CS, Hung CH, Tung WC, Kee KM, Chen CH, Hu TH, Lee CM, Lu SN. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan. J Gastroenterol Hepatol. 2010 May;25(5):964-9. doi: 10.1111/j.1440-1746.2009.06194.x.</citation>
    <PMID>20546451</PMID>
  </reference>
  <reference>
    <citation>Crisan D, Radu C, Grigorescu MD, Lupsor M, Feier D, Grigorescu M. Prospective non-invasive follow-up of liver fibrosis in patients with chronic hepatitis C. J Gastrointestin Liver Dis. 2012 Dec;21(4):375-82.</citation>
    <PMID>23256120</PMID>
  </reference>
  <reference>
    <citation>Bourliere, Marc, et al.</citation>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>March 4, 2017</last_update_submitted>
  <last_update_submitted_qc>March 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Soonchunhyang University Hospital</investigator_affiliation>
    <investigator_full_name>Sang Gyune Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>chronic hepatitis C</keyword>
  <keyword>Daclatasvir</keyword>
  <keyword>Asunaprevir</keyword>
  <keyword>fibrosis</keyword>
  <keyword>transient elastography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

